<DOC>
	<DOCNO>NCT00842088</DOCNO>
	<brief_summary>The purpose study assess safety tolerability HQK-1001 administer total 12 week ( one dose break ) subject sickle cell disease .</brief_summary>
	<brief_title>Phase 1/2 Study Evaluate Safety , Tolerability Pharmacokinetics HQK-1001 Administered Daily Patients With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Diagnosis SCD sickle beta thalassemia ( exclude Hemoglobin C ) Between 12 60 year age , inclusive At least one episode SCDrelated crisis complication ( e.g. , vasoocclusive crisis , acute chest syndrome , priapism ) per year average 3 year one episode acute chest syndrome prior 5 year Screening ( untransfused ) HbF level &gt; /= 2 % analyzed central laboratory If receive hydroxyurea therapy , must receive stable dose least 6 month Able willing give inform consent If female , must negative serum pregnancy test within 7 day dose If female , must childbearing potential define postmenopausal least 2 year surgically sterile , must agree use medically accept form contraception throughout study If sexual partner male subject WCBP , must agree use medically accept form birth control partner throughout study In view Investigator , able comply necessary study procedure Red blood cell ( RBC ) transfusion within 3 month prior begin study medication Participation regular blood transfusion program More 4 hospitalization acute sickle cellrelated event previous 12 month An acute vasoocclusive event within 3 week prior receive first dose study medication Pulmonary hypertension require oxygen QTc &gt; 450 msec screen Alanine transaminase ( ALT ) &gt; 3X upper limit normal ( ULN ) Creatinine phosphokinase ( CPK ) &gt; 20 % ULN Serum creatinine &gt; 1.2 mg/dL An acute illness ( e.g. , febrile , gastrointestinal [ GI ] , respiratory ) within 72 hour prior receive first dose study medication History syncope , clinically significant dysrhythmias resuscitation sudden death Chronic opiate use , view Investigator , could confound evaluation investigational drug Current abuse alcohol drug Received another investigational agent within 4 week , 5 halflives , whichever longer , prior administration study medication Currently pregnant breast feeding child Known infection HIV1 Infection hepatitis B hepatitis C patient currently therapy place therapy trial</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>